靶点- |
|
|
|
|
非在研适应症- |
最高研发阶段临床前 |
首次获批国家/地区- |
首次获批日期- |
Clinical Research of Human Retinal Pigment Epithelial (HuRPE) Cell Injection on Atrophy of High Myopia Macular Area
To evaluate the safety and tolerability of human retinal pigment epithelial (HuRPE) cell injection subretinal transplantation for atrophy of high myopia macular area, and to explore the maximum tolerated dose (MTD).
Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis by Primary Retinal Pigment Epithelial Cells Transplantation
Early Phase I Study of the Safety and Preliminary Efficacy of Human primary Retinal Pigment Epithelial (HuRPE) Cells Subretinal Transplantation in Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA) Patients
100 项与 江苏艾尔康生物医药科技有限公司 相关的临床结果
0 项与 江苏艾尔康生物医药科技有限公司 相关的专利(医药)
100 项与 江苏艾尔康生物医药科技有限公司 相关的药物交易
100 项与 江苏艾尔康生物医药科技有限公司 相关的转化医学